AstraZeneca (AZN.L) released data from a late-stage trial, where they combined their highly successful cancer drug, Tagrisso, with chemotherapy to treat a specific type of lung cancer. This development has set a significant benchmark for Johnson & Johnson’s (JNJ.N) competing treatment, according to analysts.
A preliminary summary of the Phase 3 trial, named FLAURA2, was made public in May, and the comprehensive data was unveiled at the World Conference on Lung Cancer in Singapore on Monday.
The results from FLAURA2 demonstrated that when chemotherapy is added to Tagrisso, the risk of disease progression or death is reduced by 38% compared to Tagrisso used in isolation.
Furthermore, the median progression-free survival (PFS) was extended to 29.4 months, representing a remarkable 9.5-month improvement over patients who received Tagrisso as a standalone treatment. Progression-free survival measures how long a patient lives without the disease worsening after treatment.
Both Barclays and UBS, in separate reports, hailed these robust results as a positive development for the British pharmaceutical giant. They noted that this outcome sets a high bar for Johnson & Johnson, which is expected to release results later this year from its head-to-head trial comparing Tagrisso in isolation to their own drug, Rybrevant, when used in combination with another medication, a study known as MARIPOSA.
UBS referred to the data as “a bit of a clearing event” that reduces risk for AstraZeneca, given that Tagrisso is seen by analysts as a key driver of growth in the short and medium term. The drug raked in an impressive $5.4 billion in sales just last year.
Despite these positive developments, AstraZeneca’s shares experienced a 3.3% dip at 1128 GMT. Two analysts cited a report in the Mail on Sunday newspaper, suggesting that the company’s CEO, Pascal Soriot, might leave the firm as early as next year. However, Healthcoach Africa could not independently verify this information, and AstraZeneca declined to comment on the report.
Back in April, shortly before the company’s new chairman, Michel Demare, assumed his role, Soriot had expressed his anticipation to collaborate with him “in the years to come.”
Barclays analysts highlighted that the FLAURA2 trial data presented on Monday included surveys involving both doctors and patients. These surveys showed a strong preference for the convenience of a single therapy compared to combinations. “We think that this raises the bar even, perhaps a bit higher, ahead of the MARIPOSA results,” the Barclays note concluded, as Johnson & Johnson is contrasting Tagrisso as a standalone therapy against their combination treatment.
Please follow and like us:
Post Views:13
Related Posts:
Healthy Monday Habits: Setting the Tone for the Entire Week Monday, the start of a new week, holds great potential for setting the tone for a successful and fulfilling week ahead. By incorporating healthy habits into our Mondays, we can create a positive and balanced…
Combining Painkillers with Hormonal Birth Control… In recent findings, commonly used pain relievers, including ibuprofen, diclofenac, and naproxen, have been associated with an increased risk of venous thromboembolism (VTE), a potentially life-threatening blood clot that can form deep within a vein,…
Nigerian Academy of Medicine Urges Government Action… The Nigerian Academy of Medicine (NAMed) has voiced deep concern over the persistent brain drain plaguing the country's healthcare sector. The exodus of skilled medical professionals, the academy lamented, has created a workforce deficit that…
Malaria: Understanding Symptoms, Treatment,… In this article, we will discuss the symptoms, treatment and prevention of malaria. Furthermore, we will highlight global efforts and challenges in eradicating malaria in our world Malaria, a life-threatening mosquito-borne disease, continues to…
